Biogen CEO: Tysabri to reach $1B in 2008

Two years ago this week, Biogen Idec relaunched Tysabri, the multiple sclerosis and Crohn's disease treatment, after a safety scare. Now, the drug is shaping up to be a blockbuster, the Wall Street Journal reports.

Tysabri was recalled in 2005 after three patients developed a rare brain infection and two died. FDA let the drug back on the market the next year under a monitoring program. Just two years later, Tysabri is expected to surpass $1 billion in annual sales, according to Biogen CEO James Mullen. First-quarter sales were $160 million, and second-quarter numbers will be announced tomorrow.

- read the WSJ article

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.